85
Views
16
CrossRef citations to date
0
Altmetric
Review

Spotlight on valsartan–sacubitril fixed-dose combination for heart failure: the evidence to date

Pages 1627-1639 | Published online: 09 May 2016

References

  • MozaffarianDBenjaminEJGoASHeart disease and stroke statistics – 2016 update: a report from the American Heart AssociationCirculation20161334e38e36026673558
  • FordESAjaniUACroftJBExplaining the decrease in U.S. deaths from coronary disease, 1980–2000N Engl J Med2007356232388239817554120
  • LozanoRNaghaviMForemanKGlobal and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010Lancet201238098592095212823245604
  • ErratumLancet2013381986762823439101
  • MoranAEForouzanfarMHRothGAThe global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 studyCirculation2014129141493150124573351
  • NicholsMTownsendNScarboroughPRaynerMTrends in age-specific coronary heart disease mortality in the European Union over three decades: 1980–2009Eur Heart J201334393017302723801825
  • AmbrosyAPFonarowGCButlerJThe global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registriesJ Am Coll Cardiol201463121123113324491689
  • HeidenreichPAAlbertNMAllenLAForecasting the impact of heart failure in the United States: a policy statement from the American Heart AssociationCirc Heart Fail20136360661923616602
  • BahramiHKronmalRBluemkeDADifferences in the incidence of congestive heart failure by ethnicity: the Multi-ethnic Study of AtherosclerosisArch Intern Med2008168192138214518955644
  • BraunwaldEThe war against heart failure: the Lancet lectureLancet2015385997081282425467564
  • GoASMozaffarianDRogerVLHeart disease and stroke statistics – 2014 update: a report from the American Heart AssociationCirculation20141293e28e29224352519
  • VigenRMaddoxTMAllenLAAging of the United States population: impact on heart failureCurr Heart Fail Rep20129436937422940871
  • DunlaySMRedfieldMMWestonSAHospitalizations after heart failure diagnosis: a community perspectiveJ Am Coll Cardiol200954181695170219850209
  • Ministério da SaúdeInformation about morbidity: hospital admission2014 Available from: http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sih/cnv/niuf.defAccessed December 24, 2015
  • No authors listedEffects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)N Engl J Med198731623142914352883575
  • No authors listedEffect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failureN Engl J Med199132552933022057034
  • PittBZannadFRemmeWJThe effect of spironolactone on morbidity and mortality in patients with severe heart failureN Engl J Med19993411070971710471456
  • McMurrayJJCONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin angiotensin aldosterone system the cornerstone of therapy for systolic heart failureEur J Heart Fail201113992993621816763
  • No authors listedEffect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)Lancet199935391692001200710376614
  • No authors listedThe Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialLancet1999353914691310023943
  • PackerMCoatsAJFowlerMBEffect of carvedilol on survival in severe chronic heart failureN Engl J Med2001344221651165811386263
  • ShibataMCFlatherMDWangDSystematic review of the impact of beta blockers on mortality and hospital admissions in heart failureEur J Heart Fail20013335135711378007
  • LevyDKenchaiahSLarsonMGLong-term trends in the incidence of and survival with heart failureN Engl J Med2002347181397140212409541
  • RogerVLWestonSARedfieldMMTrends in heart failure incidence and survival in a community-based populationJAMA2004292334435015265849
  • BarkerWHMulloolyJPGetchellWChanging incidence and survival for heart failure in a well-defined older population, 1970–1974 and 1990–1994Circulation2006113679980516461823
  • FonarowGCAbrahamWTAlbertNMFactors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HFArch Intern Med2008168884785418443260
  • GuhaKMcDonaghTHeart failure epidemiology: European perspectiveCurr Cardiol Rev20139212312723597298
  • RogerVLEpidemiology of heart failureCirc Res2013113664665923989710
  • YusufSRangarajanSTeoKCardiovascular risk and events in 17 low-, middle-, and high-income countriesN Engl J Med2014371981882725162888
  • McMurrayJJPackerMDesaiASAngiotensin-neprilysin inhibition versus enalapril in heart failureN Engl J Med201437111993100425176015
  • LevinERGardnerDGSamsonWKNatriuretic peptidesN Engl J Med199833953213289682046
  • BaxterGFThe natriuretic peptidesBasic Res Cardiol2004992717514963664
  • PandeyKNBiology of natriuretic peptides and their receptorsPeptides200526690193215911062
  • VolpeMNatriuretic peptides and cardio-renal diseaseInt J Cardiol2014176363063925213572
  • PotterLRAbbey-HoschSDickeyDMNatriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functionsEndocr Rev2006271477216291870
  • RubattuSSciarrettaSValentiVStanzioneRVolpeMNatriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseasesAm J Hypertens200821773374118464748
  • VolpeMCarnovaliMMastromarinoVThe natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatmentClin Sci (Lond)20161302577726637405
  • SonnenbergJLSakaneYJengAYIdentification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidneyPeptides1988911731802966343
  • SeguraJRuilopeLMDual-acting angiotensin receptor-neprilysin inhibitionCurr Hypertens Rep2011131747821046489
  • BevanEGConnellJMDoyleJCandoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertensionJ Hypertens19921076076131321186
  • RichardsAMWittertGACrozierIGChronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin IIJ Hypertens19931144074168390508
  • McDowellGCoutieWShawCBuchananKDStruthersADNichollsDPThe effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptidesBr J Clin Pharmacol19974333293329088591
  • FerroCJSprattJCHaynesWGWebbDJInhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivoCirculation19989723232323309639376
  • AndoSRahmanMAButlerGCSennBLFlorasJSComparison of candoxatril and atrial natriuretic factor in healthy men: effects on hemodynamics, sympathetic activity, heart rate variability, and endothelinHypertension1995266 Pt 2116011667498988
  • ClelandJGSwedbergKLack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failureLancet19983519116165716589620738
  • BurnettJCJrVasopeptidase inhibition: a new concept in blood pressure managementJ Hypertens199917Suppl 1S37S43
  • RoblJASunCQStevensonJDual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidaseJ Med Chem19974011157015779171867
  • TrippodoNCRoblJAAsaadMMFoxMPanchalBCSchaefferTREffects of omapatrilat in low, normal, and high renin experimental hypertensionAm J Hypertens1998113 Pt 13633729544878
  • LiaoWCVesterqvistODelaneyCPharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjectsBr J Clin Pharmacol200356439540612968984
  • MitchellGFIzzoJLJrLacourcièreYOmapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the Conduit Hemodynamics of Omapatrilat International Research StudyCirculation2002105252955296112081987
  • RouleauJLPfefferMAStewartDJComparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trialLancet2000356923061562010968433
  • PackerMCaliffRMKonstamMAComparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)Circulation2002106892092612186794
  • KostisJBPackerMBlackHRSchmiederRHenryDLevyEOmapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trialAm J Hypertens200417210311114751650
  • FryerRMSegretiJBanforPNEffect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedemaBr J Pharmacol2008153594795518084312
  • BlumbergALDennySEMarshallGRNeedlemanPBlood vessel-hormone interactions: angiotensin, bradykinin, and prostaglandinsAm J Physiol19772323H305H310842686
  • CampbellDJVasopeptidase inhibition: a double-edged sword?Hypertension200341338338912623931
  • BraunwaldEThe path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failureJ Am Coll Cardiol201565101029104125766951
  • GuJNoeAChandraPAl-FayoumiSLigueros-SaylanMPharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor(ARNi)J Clin Pharmacol201050440141419934029
  • HegdeLGYuCRennerTConcomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the ratJ Cardiovasc Pharmacol201157449550421297495
  • CicardiMZingaleLCBergamaschiniLAgostoniAAngioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatmentArch Intern Med2004164891091315111379
  • MistryNBWestheimASKjeldsenSEThe angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trialsExpert Opin Pharmacother20067557558116553573
  • KsanderGMGhaiRDde JesusRDicarboxylic acid dipeptide neutral endopeptidase inhibitorsJ Med Chem19953810168917007752193
  • RademakerMTCharlesCJEspinerEANichollsMGRichardsAMKosoglouTCombined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin IIJ Cardiovasc Pharmacol19983111161259456286
  • McMurrayJJAdamopoulosSAnkerSDESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCEur Heart J201233141787184722611136
  • YancyCWJessupMBozkurtB2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesJ Am Coll Cardiol20136216e147e23923747642
  • JessupMNeprilysin inhibition – a novel therapy for heart failureN Engl J Med2014371111062106425176014
  • LewingtonSClarkeRQizilbashNPetoRCollinsRAge-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesLancet200236093491903191312493255
  • BlankfieldRPTo the editor: the PARADIGM-HF trialCleve Clin J Med201683316726974982
  • No authors listedEffect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractionsN Engl J Med1992327106856911463530
  • CohnJNJohnsonGZiescheSA comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failureN Engl J Med199132553033102057035
  • No authors listedClinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison: the NETWORK investigatorsEur Heart J19981934814899568453
  • NanasJNAlexopoulosGAnastasiou-NanaMIOutcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter studyJ Am Coll Cardiol20003672090209511127445
  • KomajdaMLutigerBMadeiraHTolerability of carvedilol and ACE-inhibition in mild heart failure: results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN)Eur J Heart Fail20046446747515182773
  • Messner PellencPRudnickiALeclercqFGrolleauREnalapril in the treatment of mild-to-moderate heart failure in general medical practice: a prospective and multicentre study concerning 17,546 patientsActa Cardiol19955031872017676758
  • McMurrayJJPackerMDesaiASDual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF)Eur J Heart Fail20131591062107323563576
  • SabeMAJacobMSTaylorDOIn reply: the PARADIGM-HF trialCleve Clin J Med201683316716826974983
  • CorreiaLCRassiAJrParadigm-HF: a paradigm shift in heart failure treatment?Arq Bras Cardiol20161061777926815651
  • SabeMAJacobMSTaylorDOA new class of drugs for systolic heart failure: the PARADIGM-HF studyCleve Clin J Med2015821069370126469827
  • PackerMMcMurrayJJVDesaiASAngiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failureCirculation20151311546125403646
  • JhundPSFuMBayramEEfficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HFEur Heart J201536382576258426231885
  • KaplinskyEPARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?J Geriatr Cardiol201512547047326512236
  • BrownNJRayWASnowdenMGriffinMRBlack Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedemaClin Pharmacol Ther19966018138689816
  • SolomonSDClaggettBDesaiASInfluence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (LCZ696) in heart failure with reduced ejection fraction: the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trialCirc Heart Fail201693e00274426915374
  • BhardwajAJanuzziJLJrNatriuretic peptide-guided management of acutely destabilized heart failure: rationale and treatment algorithmCrit Pathw Cardiol20098414615019952548
  • MotiwalaSRJanuzziJLJrThe role of natriuretic peptides as biomarkers for guiding the management of chronic heart failureClin Pharmacol Ther2013931576723187878
  • VolpeMRubattuMBurnettJJrNatriuretic peptides in cardiovascular diseases: current use and perspectivesEur Heart J201435741942524227810
  • CharlesCJEspinerEANichollsMGClearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheepAm J Physiol19962712 Pt 2R373R3808770137
  • SolomonSDZileMPieskeBThe angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trialLancet201238098511387139522932717
  • KristensenSLPreissDJhundPSRisk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trialCirc Heart Fail201691e00256026754626
  • MinersJSBaruaNKehoePGGillSLoveSAβ-degrading enzymes: potential for treatment of Alzheimer diseaseJ Neuropathol Exp Neurol2011701194495922002425
  • NalivaevaNNBelyaevNDKerridgeCTurnerAJAmyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer’s diseaseFront Aging Neurosci2014623525278875
  • Novartis PharmaceuticalsEfficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients with Preserved Ejection Fraction (PARAGON-HF) Available from: https://clinicaltrials.gov/ct2/show/NCT01920711. NLM identifier: NCT01920711Accessed January 4, 2016
  • DawsonLAMaitlandNJTurnerAJUsmaniBAStromal-epithelial interactions influence prostate cancer cell invasion by altering the balance of metallopeptidase expressionBr J Cancer20049081577158215083188
  • SmollichMGötteMYipGWOn the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancerBreast Cancer Res Treat2007106336136917295044
  • Center for Drug Evaluation and ResearchApplication number: 207620orig1s000 – summary review2015 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207620Orig1s000SumR.pdfAccessed January 4, 2016
  • RuilopeLMDukatABöhmMLacourcièreYGongJLefkowitzMPBlood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator studyLancet201037597221255126620236700
  • KarioKSunNChiangFTEfficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled studyHypertension201463469870524446062
  • KarioKTamakiYOkinoNGotouHZhuMZhangJLCZ696, a first-in-class angiotensin receptor-neprilysin inhibitor: the first clinical experience in patients with severe hypertensionJ Clin Hypertens (Greenwich)201618430831426402918
  • LewisEJHunsickerLGBainRPThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathyN Engl J Med199332920145614628413456
  • RuggenentiPPernaAGherardiGRenoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuriaLancet1999354917635936410437863
  • BrennerBMCooperMEde ZeeuwDEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med20013451286186911565518
  • LipkinGWDawnayABHarwoodSMCattellWRRaineAEEnhanced natriuretic response to neutral endopeptidase inhibition in patients with moderate chronic renal failureKidney Int19975237928019291201
  • JudgePHaynesRLandrayMJBaigentCNeprilysin inhibition in chronic kidney diseaseNephrol Dial Transplant201530573874325140014
  • Mattace-RasoFUvan der CammenTJHofmanAArterial stiffness and risk of coronary heart disease and stroke: the Rotterdam StudyCirculation2006113565766316461838
  • WeberTAuerJO’RourkeMFArterial stiffness, wave reflections, and the risk of coronary artery diseaseCirculation2004109218418914662706
  • FordMLTomlinsonLAChapmanTPRajkumarCHoltSGAortic stiffness is independently associated with rate of renal function decline in chronic kidney disease stages 3 and 4Hypertension20105551110111520212269
  • RomanMJDevereuxRBKizerJRCentral pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart StudyHypertension200750119720317485598
  • BooysenHLNortonGRMasekoMJAortic, but not brachial blood pressure category enhances the ability to identify target organ changes in normotensivesJ Hypertens20133161124113023552129
  • RomanMJOkinPMKizerJRLeeETHowardBVDevereuxRBRelations of central and brachial blood pressure to left ventricular hypertrophy and geometry: the Strong Heart StudyJ Hypertens201028238438820051906
  • WilliamsBCockcroftJRKarioKRationale and study design of the Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor with Angiotensin Receptor Blocker Measuring Arterial Stiffness in the Elderly (PARAMETER) studyBMJ Open201442e004254
  • YoungJBDunlapMEPfefferMAMortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trialsCirculation2004110172618262615492298
  • PittBSegalRMartinezFARandomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly study, ELITE)Lancet199734990547477529074572
  • PfefferMAMcMurrayJJVelazquezEJValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothN Engl J Med2003349201893190614610160
  • CohnJNTognoniGA randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failureN Engl J Med2001345231667167511759645
  • KlaiberMKruseMVölkerKNovel insights into the mechanisms mediating the local antihypertrophic effects of cardiac atrial natriuretic peptide: role of cGMP-dependent protein kinase and RGS2Basic Res Cardiol2010105558359520352235
  • KimDAizawaTWeiHAngiotensin II increases phosphodi-esterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signalingJ Mol Cell Cardiol200538117518415623434
  • FrantzSKlaiberMBabaHAStress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase IEur Heart J201334161233124422199120